PMID- 25268709
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20220408
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 9
IP  - 9
DP  - 2014
TI  - Effectiveness and safety of chemotherapy combined with dendritic cells 
      co-cultured with cytokine-induced killer cells in the treatment of advanced 
      non-small-cell lung cancer: a systematic review and meta-analysis.
PG  - e108958
LID - 10.1371/journal.pone.0108958 [doi]
LID - e108958
AB  - BACKGROUND: Lung cancer, particularly non-small-cell lung cancer (NSCLC) is the 
      leading cause of cancer mortality. Chemotherapy combined dendritic cells 
      co-cultured with cytokine-induced killer cells (DC-CIK) immunotherapy has been 
      applied in advanced NSCLC patients' treatment, but couldn't provide consistent 
      beneficial results. Therefore, it is necessary to evaluate the efficiency and 
      safety of combination therapy to promote the application. METHODS: A literature 
      search for randomized controlled trials of NSCLC was conducted in PubMed 
      database. Before meta-analysis was performed, studies were evaluated 
      heterogeneity. Pooled risk ratios (RRs) were estimated and 95% confidence 
      intervals (CIs) were calculated using a fixed-effect model. Sensitivity analysis 
      was also performed. RESULTS: Six eligible trials were enrolled. Efficiency and 
      safety of chemotherapy followed by DC-CIK immunotherapy (experimental group) and 
      chemotherapy alone (control group) were compared. 1-year overall survival (OS) 
      (P = 0.02) and progression free survival (PFS) (P = 0.005) in the experimental 
      group were significantly increased compared with the control. Disease control 
      rate (DCR) (P = 0.006) rose significantly in experimental group. However, no 
      significant differences between the two groups were observed in 2-year OS 
      (P = 0.21), 2-year PFS (P = 0.10), overall response rate (ORR) (P = 0.76) and 
      partial response (PR) (P = 0.22). Temporary fever, anemia, leukopenia and nausea 
      were the four major adverse events (AEs) treated by chemotherapy. The incidence 
      of anemia, leukopenia and nausea in the experimental group was obviously lower 
      than the control group. Temporary fever rate was higher in experimental group 
      than that in the control, but could be alleviated by taking sufficient rest. 
      CONCLUSIONS: Chemotherapy combined with DC-CIK immunotherapy showed superiority 
      in DCR, 1-year OS and PFS, and no more AEs appeared, however, there was no 
      significant improvement in ORR, PR, 2-year OS and PFS. As a whole, the 
      combination therapy is safer but modest in efficacy for advanced NSCLC patients.
FAU - Han, Rui-xian
AU  - Han RX
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China; Tianjin University of Traditional Chinese Medicine, Tianjin, 
      China.
FAU - Liu, Xu
AU  - Liu X
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China.
FAU - Pan, Pan
AU  - Pan P
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China; Tianjin University of Traditional Chinese Medicine, Tianjin, 
      China.
FAU - Jia, Ying-jie
AU  - Jia YJ
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China.
FAU - Yu, Jian-chun
AU  - Yu JC
AD  - First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, 
      Tianjin, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PT  - Systematic Review
DEP - 20140930
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/mortality/*therapy
MH  - Coculture Techniques
MH  - Cytokine-Induced Killer Cells/*cytology
MH  - Databases, Factual
MH  - Dendritic Cells/cytology/*transplantation
MH  - Disease-Free Survival
MH  - Humans
MH  - Immunotherapy
MH  - Lung Neoplasms/drug therapy/mortality/*therapy
MH  - Remission Induction
MH  - Survival Rate
PMC - PMC4182599
COIS- Competing Interests: The authors have declared that no competing interests exist.
EDAT- 2014/10/01 06:00
MHDA- 2015/06/17 06:00
PMCR- 2014/09/30
CRDT- 2014/10/01 06:00
PHST- 2013/12/30 00:00 [received]
PHST- 2014/09/06 00:00 [accepted]
PHST- 2014/10/01 06:00 [entrez]
PHST- 2014/10/01 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
PHST- 2014/09/30 00:00 [pmc-release]
AID - PONE-D-13-54665 [pii]
AID - 10.1371/journal.pone.0108958 [doi]
PST - epublish
SO  - PLoS One. 2014 Sep 30;9(9):e108958. doi: 10.1371/journal.pone.0108958. 
      eCollection 2014.